Legal & General Group
TTNP

Legal & General Group’s Titan Pharmaceuticals TTNP Stock Holding History

Legal & General Group’s Portfolio TTNP Stock Details TTNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-9
Closed -$60K – 3322
2017
Q2 		$60K Buy
9
+8
+800% +$74.4K ﹤0.01% 2859
2017
Q1 		$12K Buy
+1
New +$14.1K ﹤0.01% 3171
2016
Q4 		– Hold
0
– – – 3271

Other funds holding TTNP

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
MERSOM
Municipal Employees' Retirement System of Michigan Lansing, Michigan $8.81B AUM 10.88% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
WPA
Winning Points Advisors Boca Raton, Florida $74.8M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Legal & General Group's TTNP Position: Q3 2017 in Review

Legal & General Group sold out of Titan Pharmaceuticals (TTNP) in Q3 2017, closing a stake of 9 shares — an estimated $60K sold.

Legal & General Group first reported a position in TTNP in Q1 2017 and held it in 2 quarters. The position peaked at $60K in Q2 2017. 24 funds tracked by Wall St. Rank hold TTNP as of Q3 2017.

  • Legal & General Group reported no remaining Titan Pharmaceuticals position as of Q3 2017 after selling out during the quarter.
  • Legal & General Group sold 9 Titan Pharmaceuticals shares in Q3 2017, an estimated $60K.
  • Legal & General Group first reported a position in Titan Pharmaceuticals in Q1 2017 and held it in 2 quarters.
  • Legal & General Group's Titan Pharmaceuticals position peaked at $60K in Q2 2017.
  • 24 funds tracked by Wall St. Rank held Titan Pharmaceuticals as of Q3 2017.

Based on Legal & General Group's 13F filing for Q3 2017, filed 9 Nov 2017.